In summary, in this study, using multivariable logistic regression analyses, we provided evidence that pre-treatment serum inflammation markers IL-6, TREM-1, and LCN2 at specified levels could be used as predictors of cervical cancer, and IL-6 and LCN2 could be used as predictors of an increased chance of advanced-stage (III–IV stages) cervical cancer. The gene discussed is LCN2; the disease is cervical cancer.